Key facts
- This page summarizes aMoon Growth Fund Limited Partnership's Form 4 filing for Ayala Pharmaceuticals, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 23 Oct 2023, 06:43.
aMoon Growth Fund Limited Partnership - 18 Oct 2023 Form 4 Insider Report for Ayala Pharmaceuticals, Inc.
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 18 Oct 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 23 Oct 2023, 06:43:18 UTC
- Prior SEC filing
- 30 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
-
/s/ Yair Schindel, on behalf of himself and the sole shareholder of aMoon General Partner Ltd., the sole General Partner of aMoon Growth Fund G.P. Limited Partnership, the sole General Partner of aMoon Growth Fund,...
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
aMoon Growth Fund Limited Partnership filed Form 4 for Ayala Pharmaceuticals, Inc. on 23 Oct 2023.
Change
- Previous filing in this sequence was filed on 30 Jan 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADXS
transaction
Common Stock
Other
- Transaction value
- $0
- Shares
- 0
- Change %
- 0%
- Price
- $0.000000*
- Shares after
- 560,602
- Date
- 18 Oct 2023
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
aMoon Growth Fund Limited Partnership is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
This Form 4 is filed to report that the beneficial interest of the Reporting Person in Ayala Pharmaceuticals, Inc., (the "Registrant") was reduced below 10% due to dilution resulting from issuance of approximately 5,913,480 shares of the Common Stock of the Registrant on October 18, 2023 to the former holders of Biosight Ltd. ("Biosight") upon the consummation on October 18, 2023 of the transaction contemplated by the Agreement and Plan of Merger and Reorganization, dated July 26, 2023, by and among the Registrant, Advaxis Israel Ltd. and Biosight. The transaction is more fully described in the Registrant's Form 8-K filed with the Securities and Exchange Commission on October 20, 2023.
Footnote F2
The reported shares are held of record by aMoon Growth Fund Limited Partnership ("aMoon Growth Fund"). aMoon Growth Fund G.P. Limited Partnership ("aMoon Growth Fund G.P.") is the sole General Partner of aMoon Growth Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon Growth Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel may have been deemed to have shared voting and investment power with respect to the shares held of record by aMoon Growth Fund. Each of aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Growth Fund except to the extent of its or his pecuniary interest therein, if any.